Adding Bevacizumab Effective in Chinese Patients with Nonsquamous Lung Cancer

Share this content:

the Cancer Therapy Advisor take:

The addition of bevacizumab to carboplatin/paclitaxel was well tolerated and resulted in a clinically meaningful treatment benefit in Chinese patients with advanced nonsquamous non-small cell lung cancer (NSCLC), a new study published online early in the Journal of Clinical Oncology has shown.

For the phase III trial, researchers enrolled 276 Chinese patients with locally advanced, metastatic, or recurrent advanced nonsquamous NSCLC and randomly assigned them 1:1 to receive carboplatin AUC 6 intravenously and paclitaxel 175mg/m2 intravenously on day 1 every 21 days for ≤ six cycles, with placebo or bevacizumab 15mg/kg intravenous on day 1 of each cycle. Patients received treatment until disease progression, unacceptable toxicity, or death.

Results showed that median progression-free survival was 9.2 months with bevacizumab and 6.5 months with placebo (HR = 0.40; 95% CI: 0.29-0.54; P < 0.001). In addition, objective response rate was 54% and 26% with bevacizumab and placebo, respectively.

In regard to safety, adverse events were similar to those observed in previous studies of bevacizumab plus carboplatin/paclitaxel in patients with NSCLC.

Addition of bevacizumab to carboplatin/paclitaxel well tolerated in Chinese patients with nonsquamou
Addition of bevacizumab to carboplatin/paclitaxel well tolerated in Chinese patients with nonsquamous NSCLC.
The phase III BEYOND trial was undertaken to confirm in a Chinese patient population the efficacy seen with first-line bevacizumab plus platinum doublet chemotherapy in globally conducted studies.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs